



TECHNOLOGY AVAILABLE FOR TRANSFER

UNMET NEED & OPPORTUNITY

- Biologics and Immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drug classes that will play key role in the market in future.¹
- The demand for anti-inflammatory drugs has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs.
- The rising demand for advanced drugs is likely to create lucrative growth opportunities for the Global Anti-inflammatory Drugs.
- Global Anti-inflammatory therapeutics market is projected to US\$ 130.6 Billion by 2026 with CAGR of 8.5% throughout the forecast period from 2018 to 2026.
- Commercially available Biologic Anti-inflammatory drugs are used essentially for Arthritis patients and can be categorized in three a. TNF inhibitor, b. B-cell inhibitors, and c. Interleukin-1 blockers.
- The present invention provides a broad-spectrum novel, safer anti-inflammatory biological candidate that targets inhibition of Mast cells.

TECHNOLOGY

- The technology is based on mast cells inhibition by a recombinant protein based drug – SM01 isolated from *M. tuberculosis*
- SM01 is a member of the PPE family of Mycobacterium tuberculosis. The present drug candidate is truncated smaller version of SM01 sequence for ease of delivery.
- The designed SM01 short protein have been shown to help fast recovery from inflammation in mice paw which was monitored for 21days after single application as demonstrated in Figure 1.

References

1. <https://www.researchandmarkets.com/reports/4564280/global-anti-inflammatory-therapeutics-market>
2. <https://www.medgadget.com/2019/08/anti-inflammatory-therapeutics-market-perception-to-cross-106-1-bn-by-2020.html>

KEY FEATURES

The broad-spectrum anti-inflammatory biological drug candidate is:

- Non-steroidal
- Mast cell inhibitor (disruption of first line inflammatory effect)
- Effective in single injectable dose
- Enables scar-less wound

STAGE OF DEVELOPMENT

- The technology is at R&D stage with primary proof of concept data.




Figure1: The rPPE2 reduces paw edema induced by

INTELLECTUAL PROPERTY

Patent application filed in India in 2018

LICENSING OPPORTUNITY

BCIL is looking for a suitable industrial partner for development and commercialization of Anti-inflammatory drug candidate

CONTACT:

Dr. Yogmaya Verma

Deputy Manager

BIOTECH CONSORTIUM INDIA LIMITED

V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110 002

Phone: +91-11-23219064-67, 23219053 (Direct) Fax: +91-11-23219063

Email: yogmaya@biotech.co.in & info.bcil@biotech.co.in

Website: www.biotech.co.in